Okogen, Inc., a clinical-stage biotechnology company, announced that the first patient has been dosed in the EMERALD Trial, a multicenter Phase 1/2 clinical study evaluating Treyegen™ (OKG-0303) for acute infectious conjunctivitis. The first dosing took place at Ambade Eye Hospital in Nagpur, India.
Treyegen™ is being developed as a single investigational ophthalmic therapy that combines antiviral, antibacterial, and symptom-relieving mechanisms. This approach is designed to address acute infectious conjunctivitis, a condition where the underlying cause—viral or bacterial—is often unknown at the time of diagnosis. By targeting multiple pathways, Okogen aims to provide a treatment option that can be administered before the specific pathogen is identified.
The EMERALD Trial will assess the safety, tolerability, clinical outcomes, and viral and bacterial activity of Treyegen™. The study also supports the advancement of Okogen’s broader ranpirnase platform, which is being developed across multiple therapeutic areas. For full details, including downloadable images and bios, click here.
The dosing of the first patient represents a significant clinical milestone for Okogen and its ranpirnase platform. Acute infectious conjunctivitis, commonly known as pink eye, is a prevalent condition that can cause significant discomfort and lead to missed work or school days. Current treatments often target either bacterial or viral causes specifically, but without a confirmed diagnosis, physicians may prescribe antibiotics unnecessarily or provide only supportive care. A therapy that addresses both viral and bacterial targets while relieving symptoms could reduce unnecessary antibiotic use and improve patient outcomes. However, the investigational nature of Treyegen™ means that its safety and efficacy have not yet been established, and the EMERALD Trial will be critical in determining its potential role in clinical practice.
Okogen’s host-directed antiviral platform is built around ranpirnase, a compound that aims to modulate the host’s immune response rather than directly targeting the pathogen. The company is advancing ranpirnase-based therapies across four therapeutic pillars: ophthalmology, medical countermeasures, systemic antivirals, and dermatology. Ophthalmology serves as the lead clinical proving ground for the platform, with the goal of applying clinical insights, formulation expertise, and manufacturing capabilities across a broader portfolio of antiviral therapies. For more information, visit www.okogen.com.
As with any clinical-stage development, forward-looking statements regarding the potential benefits and future regulatory progress of Treyegen™ and Okogen’s platform are subject to risks and uncertainties, including those related to clinical enrollment, study outcomes, regulatory requirements, manufacturing, and financing. Actual results may differ materially. The company undertakes no obligation to update these statements except as required by applicable law.
